Ex-Pfizer staffer found guilty of insider trading after buying stock options a day before Paxlovid data reveal
A former Pfizer employee was found guilty of buying stock options a day before the company unveiled positive Covid-19 drug data.
Amit Dagar was a senior statistical program lead for the clinical trial of Paxlovid, Pfizer’s Covid antiviral, per an SEC document.
On Nov. 4, 2021, upon learning that the Paxlovid study yielded positive results, Dagar bought Pfizer call options, according to federal prosecutors. He then informed a friend, who also bought company call options, before the results were to be made public.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.